Sullivan A T, Baker D J, Drew G M
Department of Peripheral Pharmacology, Glaxo Group Research, Hertfordshire, England.
J Cardiovasc Pharmacol. 1991 May;17(5):707-17. doi: 10.1097/00005344-199105000-00004.
We compared the abilities of verapamil and nicardipine to protect the porcine myocardium from the consequences of ischaemia-reperfusion in vivo. Infusion of verapamil (50 micrograms/kg) into the left anterior descending coronary artery LAD (i.c.a.), in 15 min immediately before ligation depressed regional contractile function, reduced infarct size by 80%, and enabled contractile function to recover partially during reperfusion. Verapamil (10 micrograms/kg i.c.a.) did not depress contractile function before ligation or permit its recovery during reperfusion, despite reducing infarct size by 80%. Lower doses of verapamil were not cardioprotective. Nicardipine (10 and 30 micrograms/kg i.c.a.) depressed contractile function before ligation but did not permit its recovery during reperfusion. Nicardipine did not reduce infarct size development. Thus, drug-induced negative inotropic activity (which presumably reflects myocardial calcium channel blockade) and cardioprotection are not linked. Verapamil can markedly reduce infarct size development at a dose that exerts no detectable negative inotropic activity. This cardioprotective effect of verapamil was greatly reduced by intravenous (i.v) pretreatment with aspirin (30 mg/kg), which alone did not alter infarct size development. Thus, the cardioprotective effect of verapamil (10 micrograms/kg i.c.a.) appears to be mediated by a cyclooxygenase product, possibly prostacyclin.
我们比较了维拉帕米和尼卡地平在体内保护猪心肌免受缺血再灌注影响的能力。在结扎前15分钟,向左前降支冠状动脉(LAD)内注入维拉帕米(50微克/千克),会降低局部收缩功能,使梗死面积缩小80%,并能使收缩功能在再灌注期间部分恢复。冠状动脉内注入维拉帕米(10微克/千克),尽管梗死面积缩小了80%,但在结扎前并未降低收缩功能,在再灌注期间也未使其恢复。较低剂量的维拉帕米没有心脏保护作用。尼卡地平(冠状动脉内注入10和30微克/千克)在结扎前降低收缩功能,但在再灌注期间未使其恢复。尼卡地平没有减少梗死面积的发展。因此,药物诱导的负性肌力活性(可能反映心肌钙通道阻滞)与心脏保护作用并无关联。维拉帕米在不产生可检测到的负性肌力活性的剂量下,可显著减少梗死面积的发展。静脉注射阿司匹林(30毫克/千克)预处理可大大降低维拉帕米的这种心脏保护作用,而阿司匹林单独使用时并不会改变梗死面积的发展。因此,维拉帕米(冠状动脉内注入10微克/千克)的心脏保护作用似乎是由环氧化酶产物介导的,可能是前列环素。